NMPA Accepts Bio-Thera Solutions’ Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin®

Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application for BAT1706, a proposed biosimilar to Avastin®.
[Bio-Thera Solutions (Business Wire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

YBX1 Mediates Autophagy by Targeting p110β and Decreasing the Sensitivity to Cisplatin in NSCLC

Scientists analyzed the expression and clinical significance of Y-box binding protein 1 and markers of autophagy in NSCLC and examined their roles in regulating sensitivity to cisplatin in NSCLC.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share

Targeting Lung Cancer Stem Cells Using Combination of Tel and Docetaxel Liposomes in 3D Cultures and Tumor Xenografts

Scientists demonstrated for the first time the efficacy of Docetaxel liposomes in combination with telmisartan in 3D cultures of H460 cells by using polysaccharide-based hydrogels and also in xenograft model of Docetaxel resistant H460 derived CD133+ lung tumors.
[Toxicology and Applied Pharmacology]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer Using a Simple Blood Test

Creatv Microtech has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy and consolidated immunotherapy.
[Business Wire, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

miR-410 Induces Both Epithelial-Mesenchymal Transition and Radioresistance through Activation of the PI3K/mTOR Pathway in Non-Small Cell Lung Cancer

Scientists demonstrated that PTEN was a direct target of miR-410 by using bioinformatic tools and dual-luciferase reporter assays, and the miR-410-induced epithelial–mesenchymal transition and radioresistance were reversed by PI3K, Akt, and mTOR inhibitors or by restoring the expression of PTEN in non-small cell lung cancer cells.
[Signal Transduction and Targeted Therapy]
Full Article
Bookmark

No account yet? Register

0
Share

Antisense Oligonucleotide-Mediated Correction of CFTR Splicing Improves Chloride Secretion in Cystic Fibrosis Patient-Derived Bronchial Epithelial Cells

Researchers tested an antisense oligonucleotide targeting the cystic fibrosis (CF) transmembrane conductance regulator c.3718-2477C>T mutation and showed that it effectively blocks aberrant splicing in primary bronchial epithelial cells from CF patients with the mutation.
[Nucleic Acids Research]

Sorry, but the selected Zotpress account can't be found.

Full Article
Bookmark

No account yet? Register

0
Share

High-Capacity Poly(2-oxazoline) Formulation of TLR 7/8 Agonist Extends Survival in a Chemo-Insensitive, Metastatic Model of Lung Adenocarcinoma

Researchers showed that their unique poly(2-oxazoline)–based nanomicellar formulation of Resiquimod, an imidazoquinoline Toll-like receptor 7/8 agonist, had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti–PD-1 therapy or platinum-based chemotherapy.
[Science Advances]
Full Article
Bookmark

No account yet? Register

0
Share

3D Printed Deformable Sensors

The authors developed an in situ 3D printing system that estimated the motion and deformation of the target surface to adapt the toolpath in real time. With this printing system, a hydrogel-based sensor was printed on a porcine lung under respiration-induced deformation.
[Science Advances]
Full Article
Bookmark

No account yet? Register

0
Share

Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Adamis Pharmaceuticals Corporation announced a license to commercialize Tempol, a novel patented investigational drug for the treatment of COVID-19. The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.
[Adamis Pharmaceuticals]
Press Release
Bookmark

No account yet? Register

0
Share

Wnt/β‐Catenin Signaling Is Critical for Regenerative Potential of Distal Lung Epithelial Progenitor Cells in Homeostasis and Emphysema

Researchers identified an organoid‐forming adult distal lung epithelial progenitor cell population characterized by a low Wnt/β‐catenin activity, which was enriched in club and alveolar epithelial type II cells.
[Stem Cells]
Full Article
Bookmark

No account yet? Register

0
Share
Share